Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zopapogene Imadenovec in Pediatric Recurrent Respiratory Papillomatosis
NCT07901738Phase 3Not yet recruiting
- Sponsor
- Precigen
- Start
- Dec 2026
- Primary completion
- Jan 2029
- Countries
- 1
01
Overview
A Phase 3 trial of zopapogene imadenovec in recurrent respiratory papillomatosis (RRP), sponsored by Precigen. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
zopapogene imadenovec
03
Conditions
recurrent respiratory papillomatosis (RRP)
Beyond the preview
Go deeper on NCT07901738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07901738.